What is Leerink Partnrs’ Forecast for ABVX FY2024 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Investment analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for ABIVAX Société Anonyme in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.08) per share for the year, down from their previous estimate of ($2.93). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

Several other research analysts also recently commented on ABVX. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $38.00.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ ABVX opened at $7.38 on Thursday. ABIVAX Société Anonyme has a 12 month low of $5.50 and a 12 month high of $16.63. The stock has a 50-day moving average price of $6.73 and a two-hundred day moving average price of $8.55.

Institutional Trading of ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC bought a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $36,000. Bank of America Corp DE raised its stake in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the period. Ameriprise Financial Inc. bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $85,000. Finally, Guggenheim Capital LLC bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $92,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.